Patients characteristics in 53 patients with aCML or CNL according to mutational risk groups
| . | Group 1 (n = 7) . | Group 2 (n = 18) . | Group 3 (n = 20) . | Group 4 (n = 8) . | P . |
|---|---|---|---|---|---|
| Gender = % male (n) | 71.4% (5) | 66.7% (12) | 70% (14) | 62.5% (5) | .978 |
| Age (mean, range) | 69.5 (54.1-87.4) | 68.5 (33.0-92.50) | 72.2 (45.6-91.4) | 76.8 (66.4-84.7) | .474 |
| Median OS (mo) | 42.8 | 34.7 | 19.6 | 13.0 | <.001 |
| Transformation to AML | 0% (0) | 33.3% (6) | 40.0% (8) | 12.5% (1) | .150 |
| Median time to transformation (mo) | NR | 16.9 | 10.7 | 8.6 | .037 |
| HSCT | 16.7% (1) | 13.3% (2) | 17.6 (3) | 0% (0) | .732 |
| Cause of death | .345 | ||||
| Progression | 100% (1) | 100% (7) | 64.3% (9) | 40% (2) | |
| Bleeding | 0% (0) | 0 | 14.3% (2) | 40% (2) | |
| Other | 0% (0) | 0 | 21.4% (3) | 20% (1) | |
| Splenomegaly | 57.1% (4) | 66.7% (12) | 45% (9) | 62.5% (5) | .582 |
| Hepatomegaly | 16.7% (1) | 40% (4) | 10% (2) | 50% (1) | .194 |
| Cutaneous bleeding | 0% (0) | 10% (1) | 15% (3) | 0% (0) | .678 |
| Mucosal bleeding | 0% (0) | 10% (1) | 5% (1) | 0% (0) | .826 |
| Hemoglobin (g/L) | 72.88 | 82.74 | 79.91 | 106.00 | .631 |
| Platelets (×109/L) | 332.00 | 246.72 | 394.8 | 253.88 | .537 |
| WBCs (×109/L) | 27.23 | 53.24 | 75.18 | 93.28 | .087 |
| Neutrophils (×109/L) | 20.96 | 48.56 | 65.06 | 79.41 | .114 |
| Lymphocytes (×109/L) | 3.37 | 3.22 | 4.74 | 3.30 | .245 |
| Monocytes (×109/L) | 1.93 | 1.63 | 2.38 | 1.93 | .830 |
| Altered cytogenetics | 0% (0) | 6.7% (1) | 25.0% (4) | 0% (0) | .176 |
| . | Group 1 (n = 7) . | Group 2 (n = 18) . | Group 3 (n = 20) . | Group 4 (n = 8) . | P . |
|---|---|---|---|---|---|
| Gender = % male (n) | 71.4% (5) | 66.7% (12) | 70% (14) | 62.5% (5) | .978 |
| Age (mean, range) | 69.5 (54.1-87.4) | 68.5 (33.0-92.50) | 72.2 (45.6-91.4) | 76.8 (66.4-84.7) | .474 |
| Median OS (mo) | 42.8 | 34.7 | 19.6 | 13.0 | <.001 |
| Transformation to AML | 0% (0) | 33.3% (6) | 40.0% (8) | 12.5% (1) | .150 |
| Median time to transformation (mo) | NR | 16.9 | 10.7 | 8.6 | .037 |
| HSCT | 16.7% (1) | 13.3% (2) | 17.6 (3) | 0% (0) | .732 |
| Cause of death | .345 | ||||
| Progression | 100% (1) | 100% (7) | 64.3% (9) | 40% (2) | |
| Bleeding | 0% (0) | 0 | 14.3% (2) | 40% (2) | |
| Other | 0% (0) | 0 | 21.4% (3) | 20% (1) | |
| Splenomegaly | 57.1% (4) | 66.7% (12) | 45% (9) | 62.5% (5) | .582 |
| Hepatomegaly | 16.7% (1) | 40% (4) | 10% (2) | 50% (1) | .194 |
| Cutaneous bleeding | 0% (0) | 10% (1) | 15% (3) | 0% (0) | .678 |
| Mucosal bleeding | 0% (0) | 10% (1) | 5% (1) | 0% (0) | .826 |
| Hemoglobin (g/L) | 72.88 | 82.74 | 79.91 | 106.00 | .631 |
| Platelets (×109/L) | 332.00 | 246.72 | 394.8 | 253.88 | .537 |
| WBCs (×109/L) | 27.23 | 53.24 | 75.18 | 93.28 | .087 |
| Neutrophils (×109/L) | 20.96 | 48.56 | 65.06 | 79.41 | .114 |
| Lymphocytes (×109/L) | 3.37 | 3.22 | 4.74 | 3.30 | .245 |
| Monocytes (×109/L) | 1.93 | 1.63 | 2.38 | 1.93 | .830 |
| Altered cytogenetics | 0% (0) | 6.7% (1) | 25.0% (4) | 0% (0) | .176 |
Group 1: unmutated CSF3R without high-risk mutations. Group 2: mutated CSF3R without high-risk mutations. Group 3: unmutated CSF3R with high-risk mutations. Group 4: mutated CSF3R with high-risk mutations. High-risk mutations include CBL, CEBPA, EZH2, NRAS, TET2, U2AF1. P values (ANOVA, χ2, or Fisher exact test) are for the presence of differences between groups. Statistically significant differences are in bold.
ANOVA, analysis of variance; HSCT, hematopoietic stem cell transplant; NR, not reached.